Our Partners

CSL Behring has acquired exclusive global license rights to commercialize AMT-061 (etranacogene dezaparvovec), for the treatment of hemophilia B. Under the terms of the agreement, uniQure will complete the Phase 3 trial and scale up manufacturing for early commercial supply.

uniQure has a collaboration and license agreement with 4D Molecular Therapeutics that is focused on the identification of novel optimized AAV variants that have greatly enhanced properties for achieving higher levels of gene expression. The collaboration will evolve AAV variants with greatly improved gene delivery properties in liver and the central nervous system.

In addition, uniQure collaborates with leading academic institutions and other research organizations that are sponsoring preclinical and early-stage clinical trials of gene therapy product candidates to which the company holds specified rights.